Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Neuroleptic malignant syndrome
ADR ID BADD_A03044
ADR Hierarchy
08      General disorders and administration site conditions
08.05      Body temperature conditions
08.05.01      Body temperature altered
08.05.01.005      Neuroleptic malignant syndrome
12      Injury, poisoning and procedural complications
12.03      Exposures, chemical injuries and poisoning
12.03.01      Poisoning and toxicity
12.03.01.003      Neuroleptic malignant syndrome
15      Musculoskeletal and connective tissue disorders
15.05      Muscle disorders
15.05.04      Muscle tone abnormalities
15.05.04.015      Neuroleptic malignant syndrome
17      Nervous system disorders
17.05      Neuromuscular disorders
17.05.02      Muscle tone abnormal
17.05.02.003      Neuroleptic malignant syndrome
Description A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72) [MeSH]
MedDRA Code 10029282
MeSH ID D009459
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Neuroleptic malignant | Neuroleptic malignant syndrome | NMS | Neuroleptic malignant synd. aggr. | Malignant syndrome NOS | Neuroleptic malignant syndrome aggravated | Atypical neuroleptic malignant syndrome | Neuroleptic Malignant Syndrome | Neuroleptic Malignant Syndromes | Syndrome, Neuroleptic Malignant | Syndromes, Neuroleptic Malignant | NMS (Neuroleptic Malignant Syndrome) | NMSs (Neuroleptic Malignant Syndrome) | Neuroleptic-Induced Neuroleptic Malignant Syndrome | Neuroleptic Induced Neuroleptic Malignant Syndrome | Neuroleptic-Malignant Syndrome, Neuroleptic Induced | Neuroleptic Malignant Syndrome, Neuroleptic Induced
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01466Milnacipran hydrochloride--
BADD_D01476Mirtazapine0.000200%
BADD_D01546Nefazodone--
BADD_D01547Nefazodone hydrochloride--
BADD_D01599Olanzapine0.019576%
BADD_D01600Olanzapine pamoate--
BADD_D01636Oxazepam0.001520%
BADD_D01656Paliperidone0.046441%
BADD_D01657Paliperidone palmitate--
BADD_D01679Paroxetine0.000064%
BADD_D01682Paroxetine impurity a--
BADD_D01735Pergolide--
BADD_D01736Pergolide mesylate--
BADD_D01738Periciazine--
BADD_D01743Perphenazine--
BADD_D01765Phenytoin0.000287%
BADD_D01774Pimozide--
BADD_D01817Pramipexole0.000399%
BADD_D01848Prochlorperazine0.000244%
BADD_D01849Prochlorperazine edisylate--
BADD_D01850Prochlorperazine maleate--
BADD_D01854Promethazine0.000077%
BADD_D01855Promethazine hydrochloride--
BADD_D01864Propofol0.000179%
BADD_D01888Quetiapine0.001608%
BADD_D01951Risperidone0.007177%
BADD_D01971Rosuvastatin0.000026%
BADD_D01973Rotigotine0.001284%
BADD_D02002Selegiline--
BADD_D02010Sertraline0.000070%
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages